J Kilian Mellon

Summary

Affiliation: University of Leicester
Country: UK

Publications

  1. ncbi Chemoprevention of prostate cancer comes of age
    J K Mellon
    Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester General Hospital, Leicester, UK
    BJU Int 93:459-60. 2004
  2. ncbi The prostate care questionnaire for patients (PCQ-P): reliability, validity and acceptability
    Carolyn Tarrant
    Department of Health Sciences, University of Leicester, Leicester, UK
    BMC Health Serv Res 9:199. 2009
  3. ncbi The Prostate Care Questionnaire for Carers (PCQ-C): reliability, validity and acceptability
    Paul Sinfield
    Department of Health Sciences, University of Leicester, Leicester, UK
    BMC Health Serv Res 9:229. 2009
  4. ncbi The finasteride prostate cancer prevention trial (PCPT)--what have we learned?
    J Kilian Mellon
    Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, United Kingdom
    Eur J Cancer 41:2016-22. 2005
  5. ncbi Epidermal growth factor receptor status predicts local response to radical radiotherapy in muscle-invasive bladder cancer
    A J Colquhoun
    Department of Cancer Studies and Molecular Medicine, Clinical Sciences Unit, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK
    Clin Oncol (R Coll Radiol) 18:702-9. 2006
  6. ncbi Management of the gastrointestinal tract at the time of cystectomy
    S Jain
    Urology Group, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK
    Urol Int 77:1-5. 2006
  7. ncbi Urethral venous malformation: an unusual cause of recurrent post-coital gross haematuria in association with haematospermia
    E G Gkougkousis
    Department of Urology, Clinical Sciences Unit, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK
    Ann R Coll Surg Engl 91:532-4. 2009
  8. ncbi Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers
    S Jain
    Division of Urology, University of Leicester, Leicester General Hospital, UK
    Postgrad Med J 78:646-50. 2002
  9. ncbi Evolving immunotherapeutic strategies in bladder and renal cancer
    T R L Griffiths
    Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester General Hospital, Leicester, UK
    Postgrad Med J 80:320-7. 2004
  10. ncbi Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo
    A J Colquhoun
    Department of Cancer Studies and Molecular Medicine, Clinical Sciences Unit, Leicester General Hospital, Gwendolen Road, Leicester, LE5 4PW
    J Radiat Res 48:351-60. 2007

Collaborators

Detail Information

Publications22

  1. ncbi Chemoprevention of prostate cancer comes of age
    J K Mellon
    Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester General Hospital, Leicester, UK
    BJU Int 93:459-60. 2004
  2. ncbi The prostate care questionnaire for patients (PCQ-P): reliability, validity and acceptability
    Carolyn Tarrant
    Department of Health Sciences, University of Leicester, Leicester, UK
    BMC Health Serv Res 9:199. 2009
    ..This paper describes an evaluation of the reliability, validity and acceptability of the PCQ-P, a newly developed instrument designed to measure patient experience of prostate cancer care...
  3. ncbi The Prostate Care Questionnaire for Carers (PCQ-C): reliability, validity and acceptability
    Paul Sinfield
    Department of Health Sciences, University of Leicester, Leicester, UK
    BMC Health Serv Res 9:229. 2009
    ..This paper describes an evaluation of the reliability, validity and acceptability of the PCQ-C, a newly developed instrument designed to measure the experiences of carers of men with prostate cancer...
  4. ncbi The finasteride prostate cancer prevention trial (PCPT)--what have we learned?
    J Kilian Mellon
    Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, United Kingdom
    Eur J Cancer 41:2016-22. 2005
    ..To conclude, there is some discussion of factors, which need to be openly discussed with male patients who might be considered for finasteride therapy...
  5. ncbi Epidermal growth factor receptor status predicts local response to radical radiotherapy in muscle-invasive bladder cancer
    A J Colquhoun
    Department of Cancer Studies and Molecular Medicine, Clinical Sciences Unit, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK
    Clin Oncol (R Coll Radiol) 18:702-9. 2006
    ..We carried out an immunohistochemical study relating the clinical outcome of patients receiving radical radiotherapy for muscle-invasive bladder cancer to tumour EGFR status...
  6. ncbi Management of the gastrointestinal tract at the time of cystectomy
    S Jain
    Urology Group, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK
    Urol Int 77:1-5. 2006
    ..Early enteral feeding is a modern concept but not yet proven. In the long-term there can be problems such as diarrhoea and B12 deficiency. All of these issues are discussed in this review using the latest available evidence...
  7. ncbi Urethral venous malformation: an unusual cause of recurrent post-coital gross haematuria in association with haematospermia
    E G Gkougkousis
    Department of Urology, Clinical Sciences Unit, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK
    Ann R Coll Surg Engl 91:532-4. 2009
    ..Three cases of recurrent post-coital haematuria are described. Extensive protracted investigations pinpointed urethral varicosities as the likely cause. All patients were successfully treated with diathermy fulguration...
  8. ncbi Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers
    S Jain
    Division of Urology, University of Leicester, Leicester General Hospital, UK
    Postgrad Med J 78:646-50. 2002
    ..This review describes the current problems with PSA testing in prostate cancer diagnosis and highlights potential ways in which these may be reduced...
  9. ncbi Evolving immunotherapeutic strategies in bladder and renal cancer
    T R L Griffiths
    Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester General Hospital, Leicester, UK
    Postgrad Med J 80:320-7. 2004
    ..In this review, our current understanding of tumour immune escape is discussed. The principles and role of current immunotherapies for these tumours are described, and new areas of immunotherapeutic promise are highlighted...
  10. ncbi Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo
    A J Colquhoun
    Department of Cancer Studies and Molecular Medicine, Clinical Sciences Unit, Leicester General Hospital, Gwendolen Road, Leicester, LE5 4PW
    J Radiat Res 48:351-60. 2007
    ..Ionising radiation (IR) stimulates EGFR causing activation of cytoprotective signalling cascades and thus may be an underlying cause of radioresistance in bladder tumours...
  11. ncbi Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies
    S K Pathak
    Division of Urology, Clinical Sciences Unit, Leicester General Hospital, University of Leicester, Gwendolen Road, Leicester LE5 4PW, UK
    Eur J Cancer 41:61-70. 2005
    ..A greater understanding of the molecular events associated with oxidative stress will enhance the development of such biomarkers and should result in better strategies for the chemoprevention of prostate cancer...
  12. ncbi A review of phase III clinical trials of prostate cancer chemoprevention
    J F Thorpe
    Urology Section, Department of Cancer Studies and Molecular Medicine, University of Leicester, Clinical Sciences Unit, Leicester General Hospital, Leicester, UK
    Ann R Coll Surg Engl 89:207-11. 2007
    ..This article reviews all the completed and on-going phase III trials in prostate cancer chemoprevention...
  13. ncbi Carbonic anhydrase IX expression and outcome after radiotherapy for muscle-invasive bladder cancer
    B T Sherwood
    Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester LE1 7RH, UK
    Clin Oncol (R Coll Radiol) 19:777-83. 2007
    ..We assessed the prognostic significance of CA IX expression in patients with muscle-invasive bladder cancer treated with radiotherapy...
  14. ncbi Chemoprevention of prostate cancer by diet-derived antioxidant agents and hormonal manipulation (Review)
    S K Pathak
    Cancer Biomarkers and Prevention Group, Department of Oncology, University of Leicester, Leicester, LE2 7LX, UK
    Int J Oncol 22:5-13. 2003
    ..In parallel, reliable assays of potential biomarkers of the efficacy of intervention need to be developed and validated rigorously...
  15. ncbi ErbB receptors: possible therapeutic targets in prostate cancer?
    H L Ratan
    Division of Urology, Leicester General Hospital, Leicester, UK
    BJU Int 92:890-5. 2003
  16. ncbi Epidermal growth factor receptor and bladder cancer
    A J Colquhoun
    University Division of Urology, Leicester General Hospital, Gwendolen Road, Leicester, UK
    Postgrad Med J 78:584-9. 2002
    ....
  17. ncbi Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer
    Lynsey A McHugh
    Urology Group, Department of Cancer Studies and Molecular Medicine, University of Leicester, Clinical Sciences Unit, Leicester General Hospital, Leicester, United Kingdom
    Urology 63:619-24. 2004
  18. ncbi Androgen manipulation alters oxidative DNA adduct levels in androgen-sensitive prostate cancer cells grown in vitro and in vivo
    Sanjeev Pathak
    Cancer Biomarkers and Prevention Group, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester LE2 7LX, UK
    Cancer Lett 261:74-83. 2008
    ..001 by Mann-Whitney Test) in flutamide-treated animals compared to controls. The changes demonstrated suggest that oxidative DNA adducts may serve as biomarkers of the efficacy of androgen manipulation in chemoprevention trials...
  19. ncbi Determination of 8-oxo-2'-deoxyguanosine and creatinine in murine and human urine by liquid chromatography/tandem mass spectrometry: application to chemoprevention studies
    Friederike Teichert
    Cancer Biomarkers and Prevention Group, Department of Cancer Studies and Molecular Medicine, University of Leicester, UK
    Rapid Commun Mass Spectrom 23:258-66. 2009
    ..In conclusion, the LC/MS/MS SRM methods described here are ideally suited for the accurate determination of 8-oxodG and creatinine in urine samples from both clinical and pre-clinical studies...
  20. ncbi Concomitant chemoradiotherapy for muscle-invasive bladder cancer: the way forward for bladder preservation?
    B T Sherwood
    Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK
    Clin Oncol (R Coll Radiol) 17:160-6. 2005
    ..Further large-scale randomised trials are needed, and information regarding bladder function and quality of life after treatment is lacking at present. The importance of close follow-up and prompt salvage cystectomy is emphasised...
  21. ncbi Measurements using the alkaline comet assay predict bladder cancer cell radiosensitivity
    M A L Moneef
    Department of Cancer Studies and Molecular Medicine, Hodgkin Building, University of Leicester, Lancaster Road, PO Box 138, Leicester LE1 9HN, UK
    Br J Cancer 89:2271-6. 2003
    ..Overall, these studies demonstrate ACA to be a good predictive measure of bladder cancer cell radiosensitivity at low dose, with potential clinical application...
  22. ncbi Resveratrol--a prostate cancer chemopreventive agent?
    Hari L Ratan
    Division of Urology, University of Leicester, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK
    Urol Oncol 7:223-7. 2002
    ..Further studies to evaluate the use of this compound as a chemopreventive agent in prostate cancer are warranted...